Stewart Cole – President, Institut Pasteur, France
Stewart Cole, president of Institut Pasteur, speaks out about his aspirations as the first foreign president of the institute and the main themes of the new strategic plan. Brexit…
Address: Institut Pasteur
25,28 rue du Docteur Roux
75724 Paris CEDEX 15 – FRANCE
,France
Tel: 33 (0)1 45 68 80 00
Web: http://www.pasteur.fr/ip/easysite/pasteur/en
Since its creation in 1887, the Institut Pasteur has become famous throughout the world as a symbol of science and french culture. For 120 years, our foundation has been contributing to the prevention and treatment of infectious diseases through research, teaching and public health initiatives.
Across the globe, thousands of researchers who have been trained or are working at Institut Pasteur share the values which form the very core of the Pasteurian community: an original scientific approach, an ongoing preoccupation with applying research to public health needs, professional ethics, a desire to care for people regardless of their background or nationality, and an outward-looking attitude, sharing knowledge and expertise with the international community. These guiding principles make the Institut Pasteur a unique institution which values exchanges and partnerships.
The Institut Pasteur enjoys an independent status and has numerous other assets, with its research laboratories, technological platforms, teaching centre and medical centre all located on one campus in the heart of Paris. It also has an international network which currently counts 30 members spread over the five continents.
With its unique setup and prestigious history, the Institut Pasteur has always stood at the forefront of innovation, adapting to the rapidly developing world of biological research and its applications, in particular in the field of biotechnology.
Nowadays, the Institut Pasteur has four priorities to carry out its activities successfully :
– to target its scientific strategy towards infectious diseases, microbiology, virology and immunology;
– to adopt an outward-looking attitude, both within France, through agreements and collaborations with its partners : CNRS (French National Scientific Research Centre), Inserm (French National Institute for Health and Medical Research), universities, hospitals, industrial partners, etc., and at international level with the development of the Réseau International des Instituts Pasteur (International Network of the Institut Pasteur or RIIP), which counts 30 institutes;
– to implement transversal research programs on ambitious themes and led by young researchers;
– to preserve the foundation’s independence, in particular through increased resources from sponsorship and donations.
These priorities, upholding the traditional tasks and values of the Institut Pasteur, place it at the cutting edge of the 21st century’s scientific and human challenges.
Scientific Research in infectious diseases, microbiology, virology and immunology
Stewart Cole, president of Institut Pasteur, speaks out about his aspirations as the first foreign president of the institute and the main themes of the new strategic plan. Brexit…
Dr. Zoubir Harrat heads the Institut Pasteur d’Algérie (IPA), after having spent most of his career with the institution. He talks of the importance to prepare for the healthcare challenges…
Hechmi Louzir, general manager of the Institut Pasteur in Tunis (IPT), details the crucial role that the IPT plays in the development of the Tunisian health sector, his wide-ranging responsibilities…
The president of the Institut Pasteur talks about how they must build on their differentiating factors, with a focus on interdisciplinary research, why they are not a French institute with…
Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research…
How would you define the Institut Pasteur’s relationship with the pharmaceutical industry and how it has evolved in recent years? Since its foundation 120 years ago, the Institut Pasteur has…
Bernard Vanhove, CEO and Maryvonne Hiance, Chairman of Effimune, an immune regulation biotech, discuss their novel approach to developing immunotherapies, their partnership and commercialization strategies, their perspective on the landscape…
Dominique Costantini, the CEO of OSE Pharma, a French biotech company developing immunotherapy products against late-stage (invasive and metastatic) cancer discusses the company’s unique targeted approach based on a patented…
The President of Pfizer France reveals how the biggest challenge the French pharma industry faces is to gain credit for its contribution to improve people´s quality of life; why France…
The president of the Institut Pasteur talks about how they must build on their differentiating factors, with a focus on interdisciplinary research, why they are not a French institute with…
Mr Martinez, President of Santen France, reveals how Santen’s decision to acquire the French pharmaceutical company Novagali in 2011, was based on its desire to project itself as an innovative ophthalmic…
The president of HAS sheds light on the seemingly complex French healthcare system, explains HAS’ role within that context and provides an honest assessment of the system’s advantages and flaws.…
Mr. Finn Søndergaard, CEO of Intsel Chimos, an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse, highlights Intsel…
Mr. Michel Finance, CEO of Theradiag, a leading French player in in vitro diagnostics and the novel field of theranostics (a combination of treatment and diagnosis), discusses the major restructuring…
The president and founder of FSNB Health & Care, a healthcare consultancy, discusses his motivations behind the creation of his company, as well as the challenges and opportunities the pharmaceutical…
ALK’s Denis Delval reveals how France is number one in terms of volumes for the group and number two in terms of revenues, just behind Germany; how the four Danes…
The president and CEO of AREVA Med, the medical subsidiary of AREVA Group, the biggest nuclear company in the world, discusses the circumstances that inspired AREVA’s foray into nuclear medicine,…
The President of CEPS, the French pricing agency, reveals the issues around the launch of the hepatitis C drug Sovaldi in 2014 and of CEPS´ role to ensure that innovative products are available to all…
See our Cookie Privacy Policy Here
